Sirolimus-Induced Vascular Dysfunction. Increased Mitochondrial and Nicotinamide Adenosine Dinucleotide Phosphate Oxidase-Dependent Superoxide Production and Decreased Vascular Nitric Oxide Formation

Journal of the American College of Cardiology

Volumn 51, Issue 22, 2008, Pages 2130-2138

  Jabs, Alexander ^a   Göbel, Sebastian ^a   Wenzel, Philip ^a   Kleschyov, Andrei L ^a   Hortmann, Marcus ^a   Oelze, Matthias ^a   Daiber, Andreas ^a   Münzel, Thomas ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

NITRIC OXIDE; NITRITE; PROTEIN P67; RAPAMYCIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMOLUMINESCENCE; CONTROLLED STUDY; DESENSITIZATION; DRUG INFUSION; ELECTRON SPIN RESONANCE; ENDOTHELIAL DYSFUNCTION; ENZYME RELEASE; ENZYME SYNTHESIS; FLUORESCENCE; HEART MITOCHONDRION; MALE; NONHUMAN; OSMOTIC PUMP; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; UPREGULATION; VASCULARIZATION; VASODILATATION; WISTAR RAT;

ANIMALS; ENDOTHELIUM, VASCULAR; ENDOTHELIUM-DEPENDENT RELAXING FACTORS; IMMUNOSUPPRESSIVE AGENTS; MALE; MITOCHONDRIA, HEART; MODELS, ANIMAL; NADPH OXIDASE; NITRIC OXIDE; OXIDATIVE STRESS; RATS; RATS, WISTAR; SIROLIMUS; SUPEROXIDES; VASOCONSTRICTION; VASODILATION;

EID: 44049087413     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2008.01.058     Document Type: Article

References (44)

1. Heitzer T., Schlinzig T., Krohn K., et al. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 104 (2001) 2673-2678
2. Williams D.O., Abbott J.D., and Kip K.E. Outcomes of 6906 patients undergoing percutaneous coronary intervention in the era of drug-eluting stents: report of the DEScover Registry. Circulation 114 (2006) 2154-2162
3. Zahn R., Hamm C.W., Schneider S., et al. The sirolimus-eluting coronary stent in daily routine practice in Germany. Clin Res Cardiol 96 (2007) 548-556
4. Togni M., Windecker S., Cocchia R., et al. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol 46 (2005) 231-236
5. Hofma S.H., van der Giessen W.J., van Dalen B.M., et al. Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur Heart J 27 (2006) 166-170
6. Obata J., Kitta Y., Takano H., et al. Sirolimus-eluting stent implantation aggravates endothelial vasomotor dysfunction in the infarct-related coronary artery in patients with acute myocardial infarction. J Am Coll Cardiol 50 (2007) 1305-1309
7. Meier P., Zbinden R., Togni M., et al. Coronary collateral function long after drug-eluting stent implantation. J Am Coll Cardiol 49 (2007) 15-20
8. Jensen L.O., Maeng M., Kaltoft A., et al. Stent thrombosis, myocardial infarction, and death after drug-eluting and bare-metal stent coronary interventions. J Am Coll Cardiol 50 (2007) 463-470
9. Luscher T.F., Steffel J., Eberli F.R., et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 115 (2007) 1051-1058
10. Poon M., Marx S.O., Gallo R., et al. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest 98 (1996) 2277-2283
11. Guba M., von Breitenbuch P., Steinbauer M., et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8 (2002) 128-135
12. Harris T.E., and Lawrence Jr. J.C. TOR signaling. Sci STKE 212 (2003) re15
13. Long C., Cook L.G., Wu G.Y., and Mitchell B.M. Removal of FKBP12/12.6 from endothelial ryanodine receptors leads to an intracellular calcium leak and endothelial dysfunction. Arterioscler Thromb Vasc Biol 27 (2007) 1580-1586
14. Long C., Cook L.G., Hamilton S.L., et al. FK506 binding protein 12/12.6 depletion increases endothelial nitric oxide synthase threonine 495 phosphorylation and blood pressure. Hypertension 49 (2007) 569-576
15. Yang C., and Burt H.M. Drug-eluting stents: factors governing local pharmacokinetics. Adv Drug Deliv Rev 58 (2006) 402-411
16. Gregory C.R., Huie P., Billingham M.E., and Morris R.E. Rapamycin inhibits arterial intimal thickening caused by both alloimmune and mechanical injury. Its effect on cellular, growth factor, and cytokine response in injured vessels. Transplantation 55 (1993) 1409-1418
17. Munzel T., Sayegh H., Freeman B.A., et al. Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross-tolerance. J Clin Invest 95 (1995) 187-194
18. Kleschyov A.L., and Munzel T. Advanced spin trapping of vascular nitric oxide using colloid iron diethyldithiocarbamate. Methods Enzymol 359 (2002) 42-51
19. Oelze M., Daiber A., Brandes R.P., et al. Nebivolol inhibits superoxide formation by NADPH oxidase and endothelial dysfunction in angiotensin II-treated rats. Hypertension 48 (2006) 677-684
20. Hink U., Li H., Mollnau H., et al. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res 88 (2001) E14-E22
21. Oelze M., Warnholtz A., Faulhaber J., et al. NADPH oxidase accounts for enhanced superoxide production and impaired endothelium-dependent smooth muscle relaxation in BKbeta1-/- mice. Arterioscler Thromb Vasc Biol 26 (2006) 1753-1759
22. Lavigne M.C., Malech H.L., Holland S.M., and Leto T.L. Genetic demonstration of p47phox-dependent superoxide anion production in murine vascular smooth muscle cells. Circulation 104 (2001) 79-84
23. Daiber A., Oelze M., August M., et al. Detection of superoxide and peroxynitrite in model systems and mitochondria by the luminol analogue L-012. Free Radic Res 38 (2004) 259-269
24. Wenzel P., Mollnau H., Oelze M., et al. First evidence for crosstalk between mitochondrial and NADPH oxidase-derived reactive oxygen species in nitroglycerin-triggered vascular dysfunction. Antioxid Redox Signal (2008) In press
25. Mollnau H., Oelze M., August M., et al. Mechanisms of increased vascular superoxide production in an experimental model of idiopathic dilated cardiomyopathy. Arterioscler Thromb Vasc Biol 25 (2005) 2554-2559
26. Levin A.D., Vukmirovic N., Hwang C.W., and Edelman E.R. Specific binding to intracellular proteins determines arterial transport properties for rapamycin and paclitaxel. Proc Natl Acad Sci U S A 101 (2004) 9463-9467
27. Trapp A., and Weis M. The impact of immunosuppression on endothelial function. J Cardiovasc Pharmacol 45 (2005) 81-87
28. Lauer T., Preik M., Rassaf T., et al. Plasma nitrite rather than nitrate reflects regional endothelial nitric oxide synthase activity but lacks intrinsic vasodilator action. Proc Natl Acad Sci U S A 98 (2001) 12814-12819
29. Krotz F., Keller M., Derflinger S., et al. Mycophenolate acid inhibits endothelial NAD(P)H oxidase activity and superoxide formation by a Rac1-dependent mechanism. Hypertension 49 (2007) 201-208
30. Krotz F., Engelbrecht B., Buerkle M.A., et al. The tyrosine phosphatase, SHP-1, is a negative regulator of endothelial superoxide formation. J Am Coll Cardiol 45 (2005) 1700-1706
31. Khanna A.K., and Pieper G.M. NADPH oxidase subunits (NOX-1, p22phox, Rac-1) and tacrolimus-induced nephrotoxicity in a rat renal transplant model. Nephrol Dial Transplant 22 (2007) 376-385
32. Cai H., Griendling K.K., and Harrison D.G. The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Trends Pharmacol Sci 24 (2003) 471-478
33. Mollnau H., Wendt M., Szocs K., et al. Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ Res 90 (2002) E58-E65
34. Zhang D.X., and Gutterman D.D. Mitochondrial reactive oxygen species-mediated signaling in endothelial cells. Am J Physiol Heart Circ Physiol 292 (2007) H2023-H2031
35. Warnholtz A., Wendt M., and Munzel T. When sleeping beauty turns ugly: mitochondria in hypoxia. Arterioscler Thromb Vasc Biol 22 (2002) 525-527
36. Therade-Matharan S., Laemmel E., Carpentier S., et al. Reactive oxygen species production by mitochondria in endothelial cells exposed to reoxygenation after hypoxia and glucose depletion is mediated by ceramide. Am J Physiol Regul Integr Comp Physiol 289 (2005) R1756-R1762
37. Liu Y., Zhao H., Li H., et al. Mitochondrial sources of H2O2 generation play a key role in flow-mediated dilation in human coronary resistance arteries. Circ Res 93 (2003) 573-580
38. Brandes R.P. Triggering mitochondrial radical release: a new function for NADPH oxidases. Hypertension 45 (2005) 847-848
39. Wassmann S., Laufs U., Muller K., et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 22 (2002) 300-305
40. Warnholtz A., Nickenig G., Schulz E., et al. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system. Circulation 99 (1999) 2027-2033
41. Bauriedel G., Jabs A., Skowasch D., et al. Dendritic cells in neointima formation after rat carotid balloon injury: coordinated expression with anti-apoptotic Bcl-2 and HSP47 in arterial repair. J Am Coll Cardiol 42 (2003) 930-938
42. Jabs A., Okamoto E., Vinten-Johansen J., et al. Sequential patterns of chemokine- and chemokine receptor-synthesis following vessel wall injury in porcine coronary arteries. Atherosclerosis 192 (2007) 75-84
43. Ferron G.M., and Jusko W.J. Species differences in sirolimus stability in humans, rabbits, and rats. Drug Metab Dispos 26 (1998) 83-84
44. Udipi K., Chen M., Cheng P., et al. Development of a novel biocompatible polymer system for extended drug release in a next-generation drug-eluting stent. J Biomed Mater Res A 85 (2008) 1064-1071